Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other financing activities (2017 - 2024)

Fate Therapeutics (FATE) has disclosed Other financing activities for 4 consecutive years, with -$558000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Other financing activities fell 1000.0% year-over-year to -$558000.0, compared with a TTM value of $62000.0 through Mar 2025, down 90.3%, and an annual FY2021 reading of $133000.0, changed N/A over the prior year.
  • Other financing activities was -$558000.0 for Q2 2024 at Fate Therapeutics, down from $558000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $558000.0 in Q1 2024 and bottomed at -$558000.0 in Q2 2024.